{
  "title": "Diamond-Wofsy ITN002AI: Treating Systemic Lupus Erythematosus (SLE) Patients with CTLA4-IgG4m (RG2077) ",
  "identifier": {
    "identifier": "http://www.immport.org/immport-open/public/study/study/displayStudyDetail/SDY798",
    "identifierSource": "http://www.immport.org"
  },
  "producedBy": {  "name": "Diamond-Wofsy ITN002AI: Treating Systemic Lupus Erythematosus (SLE) Patients with CTLA4-IgG4m (RG2077) ",
  "performedBy": [
    {
      "firstName": "David",
      "lastName": "Wofsy",
      "email": "David.Wofsy@ucsf.edu",
      "affiliations": [
          {
             "name": "University of California, San Francisco"
          }
      ],
      "roles": [
          {
             "value": "Principal Investigator"
          }
      ]
    },
    {
      "firstName": "Betty",
      "lastName": "Diamond",
      "email": "bdiamond@nshs.edu",
      "affiliations": [
          {
             "name": "Columbia University"
          }
      ],
      "roles": [
          {
             "value": "Principal Investigator"
          }
      ]
    }
  ],
  "studyGroups": [
        {
          "name": "Dose-escalation",
          "size": 6
        },
        {
          "name": "CTLA4-IgG4m",
          "size": 0
        },
        {
          "name": "Control Group",
          "size": 0
        }
  ],
  
  "selectionCriteria": [
        {
          "category": "Exclusion",
          "values": [
              "moderately severe anemia (Hgb < 8 mg/dL)"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "neutropenia (< 1,500/mm3"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "thrombocytopenia (platelets < 50,000/mm3)"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "positive PPD without evidence of prior treatment or administration of BCG"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "positive PPD without evidence of prior treatment or administration of BCG"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "receipt of a live vaccine within 3 months of study enrollment"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "end-stage renal disease (creatinine clearance< 20 mL/min/1.73mg"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "history of cancer, except carcinoma in situ and treated basal and squamous cell carcinomas"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "pregnancy"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "lactation"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "weight less than 40 kg or greater than 125 kg"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "unwillingness to use a medically acceptable form of birth control"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "antiphospholipid antibody syndrome"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "? concurrent therapy with immunosuppressive agents other than prednisone and cyclophosphamide"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "use of other experimental therapeutic agents within the past 60 days"
          ]
        },
        {
          "category": "Exclusion",
          "values": [
              "severe, progressive, or uncontrolled renal, hepatic, hematological, gastrointestinal, pulmonary, cardiac, or neurological disease (or, in the investigator?s opinion, any other concomitant medical condition that places a patient at risk by participating in the study) with the exception of diseases or conditions related to active SLE"
          ]
        },
        {
          "category": "Inclusion",
          "values": [
              "diagnosis of SLE by ACR criteria"
          ]
        },
        {
          "category": "Inclusion",
          "values": [
              "age ? 18 years"
          ]
        },
        {
          "category": "Inclusion",
          "values": [
              "concurrent treatment with intravenous cyclophosphamide (500?1,000 mg/m2) for at least one of the following manifestations of lupus: WHO class III, IV, or V lupus nephritis; British Isles Lupus Assessment Group (BILAG) A score vasculitis; BILAG A score cytopenia; or BILAG A score nervous system"
          ]
        },
        {
          "category": "Inclusion",
          "values": [
              "ability to provide informed consent."
          ]
        },
        {
          "category": "Inclusion",
          "values": [
              "stable medication regimen for at least 4 weeks before study entry"
          ]
        }
  ],
  
  "types": [
      {
          "value": "Interventional"
      }
  ]
  },
  "creators": [
    {
      "firstName": "David",
      "lastName": "Wofsy",
      "email": "David.Wofsy@ucsf.edu",
      "affiliations": [
          {
             "name": "University of California, San Francisco"
          }
      ],
      "roles": [
          {
             "value": "Principal Investigator"
          }
      ]
    },
    {
      "firstName": "Betty",
      "lastName": "Diamond",
      "email": "bdiamond@nshs.edu",
      "affiliations": [
          {
             "name": "Columbia University"
          }
      ],
      "roles": [
          {
             "value": "Principal Investigator"
          }
      ]
    },
    {
      "name": "Immune Tolerance Network",
      "extraProperties": [
        {
          "category": "Catgory",
          "values": [
            {
              "value": "DAIT"
            }
          ]
        },
        {
          "category": "External Id",
          "values": [
            {
              "value": "N/A1"
            }
          ]
        },
        {
          "category": "Description",
          "values": [
            {
              "value": "Immune Tolerance Network"
            }
          ]
        }
      ]
    }
  ],
  
  "primaryPublications": [
    {
      "identifier":
        {
          "identifier": "15807196",
          "identifierSource": "pubmed"
        },
      "authorsList": "Davidson A(1), Diamond B, Wofsy D, Daikh D.",
      "title": "Block and tackle: CTLA4Ig takes on lupus.",
      "publicationVenue": "Lupus.",
      "dates": [
        {
          "date": "2005",
          "type": { "value": "publication year" }
        }
      ]
    }
  ],
  "types": [
      {
        "value": "Clinical Trial"
      },
      {
        "value": "Interventional"
      },
      {
        "value": "Autoimmune"
      }
  ],
  "dates": [
      {
          "date": "2004-09-01",
          "type": {
              "value": "actual_start_date"
          }
      },
      {
          "date": "2016-06-17",
          "type": {
              "value": "final_public_release_date"
          }
      }
  ],
  "availability": "Available for download after registration with ImmPort",
  "refinement": "Curated",
  "dimensions": [{
        "name": {
            "value": "SkinTest_SDY798"
        }
      }
      
  ],
  
  "distributions": [
      {
          "identifier": {
              "identifier": "SDY798",
              "identifierSource": "ImmPort"
          },
          "title": "Diamond-Wofsy ITN002AI: Treating Systemic Lupus Erythematosus (SLE) Patients with CTLA4-IgG4m (RG2077) ",
          "access": {
              "landingPage": "http://www.immport.org",
              "accessURL": "http://www.immport.org/immport-open/public/study/study/displayStudyDetail/SDY798",
              "types": [
                  {
                      "value": "Download tab separated files"
                  },
                  {
                      "value": "Download MySQL files and schema"
                  }
              ],
              "authorizations": [
                {
                    "value": "Registraton with ImmPort required"
                }
              ]
          },
          "storedIn": {
              "name": "ImmPort",
              "types": [
                {
                  "value": "primary repository"
                }
              ]
         },
         "licenses": [
           {
             "name": "ImmPort User Agreement",
             "version": "1.0",
             "extraProperties": [
               {
                 "category": "Link to User Agreement",
                 "values": [
                   {
                     "value": "http://www.immport.org/agreement"
                   }
                 ]
               }
             ]
           }
         ]
      }
  ],
  "acknowledges": [
    {
      "identifier": {
        "identifier": ""
      },
      "name": "Immune Tolerance Network",
      "extraProperties": [
        {
          "category": "Link",
          "values": [
            {
              "value": "https://www.fpds.gov/ezsearch/search.do?s=FPDS&q=%22IT+strategy%22+OR+%22enterprise+architecture%22+DEPARTMENT_FULL_NAME%3A%22HEALTH+AND+HUMAN+SERVICES%2C+DEPARTMENT+OF%22+PIID%3A%22HHSD2002011F41972%22+VENDOR_ADDRESS_ZIP_CODE%3A%22221027508%22+GLOBAL_VENDOR_NAME%3A%22GAVER+TECHNOLOGIES++INC.%22+VENDOR_FULL_NAME%3A%22VANGENT%2C+INC.%22+TREASURY_ACCOUNT_SYMBOL%3A%22750885%22+CONTRACTING_OFFICE_NAME%3A%22NIH%2C+NIAID+DEA+OA+OFC+ACQUISITIONS%22+VENDOR_FULL_NAME%3A%22ST.+LOUIS+UNIVERSITY%22+PRODUCT_OR_SERVICE_CODE%3A%22AB93%22+PRINCIPAL_NAICS_CODE%3A%22325414%22+VENDOR_ADDRESS_ZIP_CODE%3A%22277088990%22+PIID%3A%22HHSN266200500019C%22&indexName=awardfull&templateName=1.4.4"
            }
          ]
        }
      ]}
  ],
  "licenses": [
    {
      "name": "ImmPort User Agreement",
      "version": "1.0",
      "extraProperties": [
        {
          "category": "Link to User Agreement",
          "values": [
            {
              "value": "http://www.immport.org/agreement"
            }
          ]
        }
      ]
    }
  ],
  "description": "The purpose of this study is to examine the safety of a single dose of RG2077 in patients with systemic lupus erythematosus (SLE) who are currently receiving cyclophosphamide. This study will also determine if RG2077 is effective in decreasing disease activity in these patients."
}
